Core Viewpoint - China will include HPV (Human Papillomavirus) vaccines in its national immunization program this year, aiming to accelerate the global goal of eliminating cervical cancer by 2030 through vaccination initiatives targeted at eligible women [1] Group 1 - The National Health Commission of China announced the integration of HPV vaccines into the national immunization plan [1] - Multiple vaccination services for eligible women will be launched as part of this initiative [1] - China plans to make a concerted effort towards the World Health Organization's 2030 vaccination phase goal for the global strategy to eliminate cervical cancer [1]

Core Viewpoint - The inclusion of the HPV vaccine in China's national immunization program marks the first expansion in 18 years, aimed at improving women's health and addressing the rising incidence of cervical cancer among younger populations [2][16]. Group 1: HPV Vaccine Overview - The HPV vaccine is now part of the national immunization program, which previously focused mainly on children under six years old [2][16]. - As of now, there are six approved HPV vaccines in China, including both imported and domestic options [4][10]. - The HPV vaccine is recognized as the most effective method for preventing cervical cancer, which is primarily caused by high-risk HPV types [8][9]. Group 2: Demand and Coverage - Despite a surge in demand for HPV vaccines, the coverage rates remain low, with only 10.15% of eligible women receiving the first dose by 2022 [11][12]. - The high cost of vaccines has been a barrier to access, with imported vaccines priced between 580 to 800 RMB per dose [10][14]. - Public awareness and misconceptions about vaccine safety have also contributed to low uptake rates [15][36]. Group 3: Government Initiatives and Support - The Chinese government is committed to promoting HPV vaccination, aligning with the WHO's goal of eliminating cervical cancer by 2030 [16][28]. - Pilot programs in various cities have successfully increased vaccination rates, demonstrating the effectiveness of government-led initiatives [21][25]. - The national immunization program aims to provide equitable access to vaccines, particularly for underserved populations [34]. Group 4: Economic Considerations - The economic evaluation of HPV vaccination is crucial for justifying its inclusion in the national program, focusing on cost-effectiveness and public health benefits [27][28]. - The reduction in newborn numbers has also created budgetary space for expanding the immunization program [31][32]. - The competition among vaccine suppliers has led to significant price reductions, making vaccines more accessible [30]. Group 5: Future Prospects - The integration of HPV vaccines into the national immunization program is expected to significantly increase vaccination rates, similar to past experiences with other vaccines [37]. - Domestic manufacturers are ramping up production capacity, ensuring a stable supply of vaccines [37]. - Ongoing research and development in HPV vaccines, including the introduction of a nine-valent vaccine, indicate a positive trend in cervical cancer prevention efforts in China [37].

在公共卫生领域，国家免疫规划由政府免费提供疫苗，旨提高人口整体健康水平，无论经济状况如何，都能被惠及。在此之前，中国的免疫规划疫苗覆盖人 群以6岁以下儿童为主，比如婴儿出生后都要注射的卡介苗、乙肝疫苗等，针对青少年甚至成年人的少之又少。 近年来，有多种疫苗都曾经被广泛推荐纳入国家免疫计划，其中包括流感疫苗、肺炎疫苗等，而最终HPV疫苗成为了"幸运儿"。 智通财经记者 | 陈杨 李科文 智通财经编辑 | 谢欣 许悦 这是18年来，中国的国家免疫规划首次扩容。 9月11日，国家卫健委副主任、国家疾控局局长沈洪兵在新闻发布会上表示，今年国家将推出面向适龄女生的HPV疫苗（宫颈癌疫苗）接种服务，并且将 HPV疫苗纳入国家免疫规划，保护女性的健康。 这与其临床获益性有很大关系。2022年，国内新发宫颈癌病例达到15.07万例，整体发病呈上升趋势且日渐年轻化。HPV病毒全称为人乳头瘤病毒，主要通 过母婴、性接触和经皮肤黏膜接触传播。宫颈癌是全球唯一可预防的癌症——99.7%的宫颈癌都由高危型HPV病毒持续感染导致，世界公认预防宫颈癌最有 效手段即接种HPV疫苗。 一度高涨的需求和极低的渗透率 广州荔湾区的白鹤洞卫生服务中 ...

（原标题：HPV疫苗纳入免疫规划，重塑百亿市场与公共健康格局） 21世纪经济报道记者季媛媛 中国HPV疫苗免费接种政策在经历了从地方试点到省级推广后，如今已经进入到了国家免疫规划。 9月11日，国新办举行"高质量完成'十四五'规划"系列主题新闻发布会，介绍"十四五"时期卫生健康工作 发展成就。据介绍，今年国家将推出面向适龄女生的HPV疫苗接种服务，并且将HPV疫苗纳入国家免疫 规划，保护女性的健康。 这场始于地方试点的健康行动终于升级为国家战略，标志着中国宫颈癌防控进入新阶段。 HPV（人乳头瘤病毒）感染可引发多种疾病，高危型HPV与宫颈癌、外阴癌、阴道癌、肛门癌、口咽癌 等多种恶性肿瘤的发生密切相关，低危型HPV则是引发尖锐湿疣的主要原因。部分男性亦存在HPV感染 及相关疾病风险。接种HPV疫苗是当前公认安全、有效的一级预防手段，可显著降低HPV感染及其相关 疾病的发病率。 为了提高HPV疫苗接种率，全国多地陆续启动了适龄人群HPV疫苗接种惠民活动，以进口九价HPV疫苗 为例，可以减免最后一剂次接种费用。眼下， 我国HPV疫苗接种以二价、四价、九价为主，在推进 HPV进免规的过程中，是否会优先考虑覆盖特定价 ...

Core Viewpoint - The announcement of HPV vaccines being included in the national immunization program is expected to positively impact the HPV vaccine market and related companies, which have been struggling with declining performance [1][3][4]. Group 1: Market Response - On September 11, HPV vaccine concept stocks in the A-share market saw a rise, with notable increases in companies such as Kangla Weishi (up 3.09%), Wantai Biological Pharmacy (up 2.69%), Zhifei Biological Products (up 1.98%), and Watson Bio (up 1.71%) [1]. - The National Health Commission's announcement regarding the introduction of HPV vaccination services for eligible girls and its inclusion in the national immunization plan is a significant development [1][2]. Group 2: Industry Challenges - HPV vaccine manufacturers are currently facing challenges due to declining sales and increased competition in the market, leading to a price war [3][4]. - The performance of HPV vaccine companies has been poor, with Wantai Biological reporting a revenue of 844 million yuan, down 38.25% year-on-year, and a net loss of 144 million yuan [4]. - Watson Bio's revenue was 1.154 billion yuan, down 19.47%, with a net profit decline of 74.69% [4]. - Zhifei Biological reported a revenue of 4.919 billion yuan, down 73.06%, and a net loss of 597 million yuan, a 126.72% decline [4][5]. Group 3: Potential for Growth - The global incidence of cervical cancer is rising, particularly among younger women in China, highlighting the need for effective HPV vaccination [6]. - The World Health Organization recommends that countries include HPV vaccination in their national immunization programs, prioritizing girls aged 9 to 14 [6]. - Currently, 143 out of 194 WHO member countries have included HPV vaccines in their national immunization plans, indicating a global trend towards increased vaccination [6]. - With the supply of HPV vaccines becoming sufficient and prices decreasing, the timing for including HPV vaccines in the national immunization program in China is considered ripe [7]. - The minimum price for HPV vaccines has dropped to 27.5 yuan per dose, significantly lower than initial prices, making it more accessible [7]. - If included in the national immunization program, HPV vaccines would likely see increased sales despite lower profit margins compared to local immunization programs [7].

在9月11日国新办举行的"高质量完成'十四五'规划"系列主题新闻发布会上，国家卫生健康委副主任、 国家疾控局局长沈洪兵表示，今年国家将推出面向适龄女生的HPV（人乳头瘤病毒）疫苗接种服务，并 将HPV疫苗纳入国家免疫规划，以进一步保护女性健康。 2020年，世界卫生组织（WHO）提出"加速消除宫颈癌全球战略"，明确到2030年实现90%的女孩在15 岁前完成HPV疫苗接种的目标。 为响应WHO战略、落实《"健康中国2030"规划纲要》，2023年国家卫健委联合教育部、财政部、国家 医保局等10个部门印发《加速消除宫颈癌行动计划（2023—2030年）》（以下简称"《行动计划》"）。 文件提出，到2025年，要试点推广适龄女孩HPV疫苗接种服务；适龄妇女宫颈癌筛查率达到50%；宫颈 癌及癌前病变患者治疗率达到90%。到2030年，持续推进HPV疫苗接种试点，适龄妇女宫颈癌筛查率提 升至70%，患者治疗率保持在90%。 同时，《行动计划》提出对符合要求的国产HPV疫苗加快审评审批，鼓励有条件的地区开展接种试点。 近年来，国家卫健委等部门持续推动HPV疫苗接种。官方数据显示，截至今年6月，海南、福建、广东 等17个 ...

2025.09. 11 本文字数：2193，阅读时长大约4分钟 作者 | 第一财经 吴斯旻 时隔十七年，国家免疫规划将迎来实质性扩容， HPV疫苗会在年内被新增纳入。 11日，在国新办"高质量完成'十四五'规划"系列主题新闻发布会上，国家疾控局局长沈洪兵表示， 今年国家将推出面向适龄女生的HPV疫苗接种服务，并且将HPV疫苗纳入国家免疫规划，保护女性 的健康。 第一财经多方了解到，纳入国家免疫规划的HPV疫苗将为二价苗，优先覆盖适龄女童。HPV疫苗"扩 免"成功，也意味着国家免疫规划正由儿童疫苗转向"全生命周期疫苗接种"。不过，当接种人群从0- 6岁儿童拓展到在校适龄女生之后，接种策略如何制定、是否会探索疫苗"进校"以及是否存在补种方 案等，仍待揭晓。 宫颈癌是全球女性最常见的恶性肿瘤之一，仅次于乳腺癌的女性第二大杀手，其发病趋势越来越年轻 化。根据国家癌症中心 2024 年发布的研究显示，中国女性宫颈癌病例占全球的 23%，死亡人数占 全球的 16%。几乎所有的宫颈癌病例（99.7%)都与HPV感染有关，持续的HPV感染会有可能发展 为宫颈癌。 正因如此，HPV疫苗作为目前全世界唯一一个可以有效预防宫颈癌的 ...

Core Viewpoint - The Chinese government has included the HPV vaccine in the national immunization program, allowing eligible girls to receive the vaccine for free starting this year [2][3]. Group 1: National Immunization Program Expansion - This marks the first expansion of the national immunization program in 18 years, with the HPV vaccine being prioritized for inclusion [2]. - Since 2007, the immunization program has maintained a structure of "fourteen vaccines for fifteen diseases," with no substantial additions in vaccine types over the years [2]. - As of 2024, 147 out of 194 WHO member countries have included the HPV vaccine in their immunization programs [2]. Group 2: HPV Vaccine and Cervical Cancer - HPV is a common virus primarily transmitted through sexual contact, with persistent infection of 14 high-risk HPV types being the main cause of cervical cancer [2]. - Vaccination can prevent at least 70% of cervical cancer cases, which is critical given the rising incidence and mortality rates of cervical cancer in China [2]. - In 2022, approximately 150,000 new cervical cancer cases and about 56,000 deaths were reported in China [2]. Group 3: Local Government Initiatives - Several local governments have already initiated free HPV vaccination programs for eligible girls, with Guangdong province being one of the earliest adopters since 2022 [3][4]. - The program in Guangdong requires eligible girls to meet specific criteria, including being under 14 years old and having no prior HPV vaccination [4]. - Over 17 provinces in China have implemented similar free vaccination projects, although the distribution of these programs is uneven, with fewer initiatives in central and northeastern regions compared to eastern and southern areas [4]. Group 4: Market Impact - Following the announcement of the HPV vaccine's inclusion in the immunization program, stock prices of several HPV vaccine manufacturers rose [5]. - WanTai BioPharmaceuticals saw a 2.52% increase in stock price, while Watson Bio and Zhifei Biological also experienced stock price increases of 1.22% and 1.71%, respectively [5].

Group 1 - The Chinese government has expanded its national immunization program to include the HPV vaccine, allowing eligible individuals to receive it for free starting this year [2] - The inclusion of the HPV vaccine in the national immunization program is aimed at protecting women's health and is a significant change after 18 years of maintaining the previous immunization framework [2][3] - The HPV vaccine is known to prevent at least 70% of cervical cancer cases, which is crucial given the rising incidence and mortality rates of cervical cancer in China [2][3] Group 2 - Over 17 provinces in China have already implemented free HPV vaccination programs for eligible girls, with most following a model similar to that of Guangdong Province [4][5] - The distribution of these vaccination programs is uneven, with fewer initiatives in central, western, and northeastern regions compared to eastern and southern regions [5] - Following the announcement of the HPV vaccine's inclusion in the immunization program, stock prices of several HPV vaccine companies rose, indicating positive market sentiment [5]

二价疫苗主要预防HPV16、18型。HPV16、18型是导致宫颈癌最常见的高危型别，约占所有宫颈癌病例 的70%-80%。 宫颈癌是全球女性最常见的恶性肿瘤之一，仅次于乳腺癌的女性第二大杀手，其发病趋势越来越年轻 化。根据国家癌症中心 2024 年发布的研究显示，中国女性宫颈癌病例占全球的 23%，死亡人数占全球 的 16%。几乎所有的宫颈癌病例（99.7%)都与HPV感染有关，持续的HPV感染会有可能发展为宫颈癌。 正因如此，HPV疫苗作为目前全世界唯一一个可以有效预防宫颈癌的疫苗，一直备受关注。世界卫生组 织建议各成员国将 HPV 疫苗接种纳入国家免疫规划，优先为 9 至 14 岁女孩接种疫苗，并在《加速消除 宫颈癌全球战略》中提出 90%女孩在 15 岁前完成 HPV 疫苗接种这一目标。 时隔十七年，国家免疫规划将迎来实质性扩容， HPV疫苗会在年内被新增纳入。 11日，在国新办"高质量完成'十四五'规划"系列主题新闻发布会上，国家疾控局局长沈洪兵表示，今年 国家将推出面向适龄女生的HPV疫苗接种服务，并且将HPV疫苗纳入国家免疫规划，保护女性的健康。 第一财经多方了解到，纳入国家免疫规划的HPV疫苗将 ...